There were 1,858 press releases posted in the last 24 hours and 442,483 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image